Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

Emma Guttman-Yassky, Andrew Blauvelt, Lawrence F. Eichenfield, Amy S. Paller, April W. Armstrong, Janice Drew, Ramanan Gopalan, Eric L. Simpson

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences